Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2020 | Treating GvHD with proteasome inhibitors

Arnon Nagler • 5 Oct 2020
COMy 2020
Leukemia Bortezomib Carfilzomib Cyclosporine Methotrexate

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses the drugs that have been approved to treat graft versus host disease (GvHD) after transplantation. One option is to treat patients with proteasome inhibitors, such as bortezomib and carfilzomib. In an early-stage study, carfilzomib has shown a good response to prevent GvHD. However, the study compared responses to historical controls. Therefore, carfilzomib needs to be evaluated in a randomized setting. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.

More from Arnon Nagler

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:21
Trends in alloSCT for good-risk AML: a longitudinal study
Arnon Nagler • 9 Dec 2023
2:15
GvHD prophylaxis post-alloSCT: PTCy versus ATG
Arnon Nagler • 9 Dec 2023
2:13
Haploidentical SCT for the treatment of secondary AML
Arnon Nagler • 9 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals